CYCLOPHOSPHAMIDE
(CPM, Cytoxan, Procytox)Standard Prescription
cyclophosphamide__mg PO daily (__mg/kg/day)
cyclophosphamide__g IV Q__days (__g/m2/month)
cyclophosphamide__g IV Q__days (__g/m2/month)
Dosages
SLE, CNS Vasculitis, Systemic Vasculitis, Juvenile Dermatomyositis:
500-1000 mg/m2/dose IV
Maximum 1200 mg/dose
Dosed at various frequencies dependent on indication and protocol
Nephrotic Syndrome:
2 mg/kg/day PO for 12 weeks
Maximum: 175mg/dose
500-1000 mg/m2/dose IV
Maximum 1200 mg/dose
Dosed at various frequencies dependent on indication and protocol
Alternative Systemic Vasculitis Dosing:
15 mg/kg/dose IV q2weeks x 3 doses, then q3weeks based on response. Maximum 1200 mg/dose
Nephrotic Syndrome:
2 mg/kg/day PO for 12 weeks
Maximum: 175mg/dose
Mechanism of Action
Immune suppressant; alkylating agent.
Cyclophosphamide is an anti-neoplastic agent used to treat many types of cancer. For use in cancer, refer to individual treatment protocol.
Cyclophosphamide is also used as an immunosuppressant.
Forms Supplied
tablet: 25 mg, 50 mg
injection: 1 g /vial
BCCH suspension: 10 mg/mL
injection: 1 g /vial
BCCH suspension: 10 mg/mL
Comments
For use in oncologic indications, refer to individual treatment protocols
RNs throughout the hospital may administer cyclophosphamide; chemotherapy certification is not required
Hazardous Drug
Consider individual lifetime cumulative dose due to risk of gonadal toxicity
Adverse reactions include hemorrhagic cystitis (patients must be well hydrated during therapy), myelosuppression, nausea, vomiting, alopecia.
RNs throughout the hospital may administer cyclophosphamide; chemotherapy certification is not required
Hazardous Drug
Consider individual lifetime cumulative dose due to risk of gonadal toxicity
Adverse reactions include hemorrhagic cystitis (patients must be well hydrated during therapy), myelosuppression, nausea, vomiting, alopecia.
References
32, 44, 109, 572, 573, 574
Last Edited
2022-06-16 17:53:02